statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buy J.B. Chemicals and Pharmaceuticals; target of Rs 1920: Prabhudas Lilladher

Prabhudas Lilladher is bullish on J.B. Chemicals and Pharmaceuticalste has recommended buy rating on the stock with a target price of Rs 1920 in its research report dated May 22, 2024.

Hold J B Chemicals &amp; Pharmaceuticals: target of Rs 1800: ICICI Securities

ICICI Securities recommended hold rating on J B Chemicals &amp; Pharmaceuticals with a target price of Rs 1800 in its research report dated May 22, 2024.

Stock Radar: JSW Steel, Zydus Life, Bandhan Bank, Zee Entertainment in focus today

Anupam Rasayan India, ASK Automotive, Chemcon Speciality Chemicals, Data Patterns (India), Gujarat Ambuja Exports, Jyoti CNC Automation, Trident, and Ujjivan Small Finance Bank will release March quarter earnings on May 18.

JB Pharma Q4 net profit up 43% to Rs 126 crore

Revenue from operations came in at Rs 861.7 crore, up 13 percent from Rs 762 crore in the year-ago quarter.

JB Chem shares surge 10% to scale 52-week high on solid Q3 earnings

Strong growth in the domestic formulations segment offset sluggish international sales for JB Chem in Q3.

Drug pricing watchdog fixes retail rates for 19 formulations, including cancer pills

Cancer medication Trastuzumab manufactured by Hetero Biopharma Limited and Mankind Pharma Limited will have a ceiling price of Rs 15817.49 per vial.

J.B. Chemicals & Pharmaceuticals Ltd. is a holding company, which engages in the manufacture and trade of pharmaceutical products. It operates through the following business units: India; Russia & CIS; Global; Contrast Media; API; and Business Development. The India business unit produces medicine for gastro, cardiac, and pain management. The Russia and CIS business unit markets and sells over the counter and prescription drugs. The Global business unit commercializes generic branded medicines. The Contrast Media business unit offers radiopaque substances such as lohexol, lopamidol, diatrazoic acid, gadopentatic acid, and iodixanol. The API business unit caters active pharmaceutical ingredients which includes atenelol, clinidipine, diclofenac acid, diclofenac potassium, nifedipine, and gadopentatic acid. The Business Development business unit deals with contract manufacturing, joint ventures, marketing partners, in-licensing of products, and distribution network. The company was founded by Jyotindra Bhagwanlal Mody on December 18, 1976 and is headquartered in Mumbai, India.

Volume	95,123.00
52-Wk High	1,940.00
52-Wk Low	1,196.98

JBCHEPHARM.NSE J.B. Chemicals & Pharmaceuticals Ltd.

About

Feed

News

Sentiment

Fundamentals